Palatin Technology / voraussichtliches Marktpotential von 1,3 Mrd $ bis 2020 allein in USA (Seite 47)
eröffnet am 17.02.15 22:17:27 von
neuester Beitrag 28.02.24 20:50:54 von
neuester Beitrag 28.02.24 20:50:54 von
Beiträge: 5.764
ID: 1.207.859
ID: 1.207.859
Aufrufe heute: 0
Gesamt: 1.024.225
Gesamt: 1.024.225
Aktive User: 0
ISIN: US6960775020 · WKN: A3DTUW · Symbol: PTN
1,8960
EUR
-0,11 %
-0,0020 EUR
Letzter Kurs 22.05.24 Tradegate
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,0800 | +28,56 | |
| 2,1800 | +27,49 | |
| 1,9900 | +20,61 | |
| 10.777,50 | +19,75 | |
| 2,4200 | +17,48 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,2850 | -13,45 | |
| 10,551 | -13,94 | |
| 0,5701 | -16,77 | |
| 2,5100 | -17,43 | |
| 2,2001 | -20,57 |
Beitrag zu dieser Diskussion schreiben
Feedback
Mal ehrlich, ist das Ding hier gelutscht oder seht ihr noch irgendwelche News, die den Kurs nach oben treiben könnten?
Can We See Significant Institutional Ownership On The Palatin Technologies, Inc. (NYSEMKT:PTN) Share Register?
The big shareholder groups in Palatin Technologies, Inc. (NYSEMKT:PTN) have power over the company.
We can see that Palatin Technologies does have institutional investors; and they hold 24% of the stock. This suggests some credibility amongst professional investors.
Palatin Technologies is not owned by hedge funds. BlackRock, Inc. is currently the company’s largest shareholder with 6.9% of shares outstanding. The second and third largest shareholders are The Vanguard Group, Inc. and State Street Global Advisors, Inc., holding 4.4% and 1.6%, respectively.
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse…
The big shareholder groups in Palatin Technologies, Inc. (NYSEMKT:PTN) have power over the company.
We can see that Palatin Technologies does have institutional investors; and they hold 24% of the stock. This suggests some credibility amongst professional investors.
Palatin Technologies is not owned by hedge funds. BlackRock, Inc. is currently the company’s largest shareholder with 6.9% of shares outstanding. The second and third largest shareholders are The Vanguard Group, Inc. and State Street Global Advisors, Inc., holding 4.4% and 1.6%, respectively.
https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse…
Zaleiko
von Stocktwits
05:22 PM
$PTN
Where is everyone? I think the “Pandemic” got them... Down again for this POS
https://img.wallstreet-online.de/smilies/laugh.gif
von Stocktwits
05:22 PM
$PTN
Where is everyone? I think the “Pandemic” got them... Down again for this POS
https://img.wallstreet-online.de/smilies/laugh.gif
Does Palatin Technologies, Inc.'s (NYSEMKT:PTN) CEO Salary Compare Well With Others?
At the time of writing, our data says that Palatin Technologies, Inc. has a market cap of US$98m, and reported total annual CEO compensation of US$2.3m for the year to June 2019. While we always look at total compensation first, we note that the salary component is less, at US$505k. Importantly, there may be performance hurdles relating to the non-salary component of the total compensation. We took a group of companies with market capitalizations below US$200m, and calculated the median CEO total compensation to be US$601k.
Now let's take a look at the pay mix on an industry and company level to gain a better understanding of where Palatin Technologies stands. Speaking on an industry level, we can see that nearly 22% of total compensation represents salary, while the remainder of 78% is other remuneration. Our data reveals that Palatin Technologies allocates salary in line with the wider market.
As you can see, Carl Spana is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Palatin Technologies, Inc. is paying too much. We can better assess whether the pay is overly generous by looking into the underlying business performance. You can see a visual representation of the CEO compensation at Palatin Technologies, below.
https://finance.yahoo.com/news/does-palatin-technologies-inc…
At the time of writing, our data says that Palatin Technologies, Inc. has a market cap of US$98m, and reported total annual CEO compensation of US$2.3m for the year to June 2019. While we always look at total compensation first, we note that the salary component is less, at US$505k. Importantly, there may be performance hurdles relating to the non-salary component of the total compensation. We took a group of companies with market capitalizations below US$200m, and calculated the median CEO total compensation to be US$601k.
Now let's take a look at the pay mix on an industry and company level to gain a better understanding of where Palatin Technologies stands. Speaking on an industry level, we can see that nearly 22% of total compensation represents salary, while the remainder of 78% is other remuneration. Our data reveals that Palatin Technologies allocates salary in line with the wider market.
As you can see, Carl Spana is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Palatin Technologies, Inc. is paying too much. We can better assess whether the pay is overly generous by looking into the underlying business performance. You can see a visual representation of the CEO compensation at Palatin Technologies, below.
https://finance.yahoo.com/news/does-palatin-technologies-inc…
Antwort auf Beitrag Nr.: 63.127.951 von apano am 25.03.20 14:43:46Klingt super. Also nachkaufen oder wenigstens investiert bleiben!!
Trading Spotlight
Vom 03.03.2020
Palatin Technologies (PTN)
Let’s start off with the “penniest” of the lot. Palatin's stock is trading at $0.48 each, following a decline of nearly 40% year-to-date. Some on the Street, though, believe now is the time to snap up shares of the Cranbury, New Jersey based microcap.
Palatin develops peptide therapeutics for diseases with significant unmet medical needs. The company’s varied pipeline includes candidates for the treatment of heart failure, diabetes and inflammatory diseases.
Taking most of the headlines is Palatin’s lead product Vyleesi (Bremelanotide), a treatment for hypoactive sexual desire disorder (HSDD). Vyleesi was approved by the FDA in June 2019, and its North American rights are currently exclusively licensed to AMAG Pharmaceuticals. However, due to an internal shake up, AMAG decided recently to divest Vylessi and is currently in the search for a new US home for the drug. Palatin management believes that a new partnership should be in place in the next few months.
Cannacord’s John Newman is backing the company to find a new suitable US partner for the drug while also increasing its international presence. The 5-star analyst said, “Palatin expects to announce additional executed partnerships for Vyleesi in all worldwide geographic areas outside North America by the end of 2020. We continue to expect a robust new partner for Vyleesi near-term and await details in March on the AMAG call. We believe Vyleesi will be competitively differentiated vs. Addyi, which must be given chronically and has potentially dangerous interaction with alcohol.”
Newman, therefore, keeps his Buy rating as is, but the analyst’s price target is reduced from $4 to $3. Nevertheless, the upside potential still comes in at a moon landing 512%. (To watch Newman’s track record, click here)
Out on the Street, two other analysts are currently backing Newman’s arguments in Palatin’s favor. The additional Buy ratings add up to a Strong Buy consensus rating, along with an average price target of $2.17. The intrepid investor could be pocketing a 339% gain should the analysts’ thesis play out. (See Palatin price targets and analyst ratings on TipRanks)
Palatin Technologies (PTN)
Let’s start off with the “penniest” of the lot. Palatin's stock is trading at $0.48 each, following a decline of nearly 40% year-to-date. Some on the Street, though, believe now is the time to snap up shares of the Cranbury, New Jersey based microcap.
Palatin develops peptide therapeutics for diseases with significant unmet medical needs. The company’s varied pipeline includes candidates for the treatment of heart failure, diabetes and inflammatory diseases.
Taking most of the headlines is Palatin’s lead product Vyleesi (Bremelanotide), a treatment for hypoactive sexual desire disorder (HSDD). Vyleesi was approved by the FDA in June 2019, and its North American rights are currently exclusively licensed to AMAG Pharmaceuticals. However, due to an internal shake up, AMAG decided recently to divest Vylessi and is currently in the search for a new US home for the drug. Palatin management believes that a new partnership should be in place in the next few months.
Cannacord’s John Newman is backing the company to find a new suitable US partner for the drug while also increasing its international presence. The 5-star analyst said, “Palatin expects to announce additional executed partnerships for Vyleesi in all worldwide geographic areas outside North America by the end of 2020. We continue to expect a robust new partner for Vyleesi near-term and await details in March on the AMAG call. We believe Vyleesi will be competitively differentiated vs. Addyi, which must be given chronically and has potentially dangerous interaction with alcohol.”
Newman, therefore, keeps his Buy rating as is, but the analyst’s price target is reduced from $4 to $3. Nevertheless, the upside potential still comes in at a moon landing 512%. (To watch Newman’s track record, click here)
Out on the Street, two other analysts are currently backing Newman’s arguments in Palatin’s favor. The additional Buy ratings add up to a Strong Buy consensus rating, along with an average price target of $2.17. The intrepid investor could be pocketing a 339% gain should the analysts’ thesis play out. (See Palatin price targets and analyst ratings on TipRanks)
Hallo, ist noch jamand da? Das Bord von PTN als auch den Anleger hat es die Sprache verschlagen nach dem jüngsten Abverkauf.
Antwort auf Beitrag Nr.: 62.827.709 von stegonatus am 28.02.20 17:23:10Ja. Top Ansage!
Läuft doch
Antwort auf Beitrag Nr.: 62.822.756 von opportoni am 28.02.20 12:28:05Denke auch, dass das Risiko nach unten wohl nur noch sehr begrenzt sein kann.
Durchsuchen
